The FA Community Needs Your Help to Advance a Potential Treatment

The FA Community Needs Your Help to Advance a Potential Treatment

282976

The FA Community Needs Your Help to Advance a Potential Treatment

The Friedreich’s ataxia (FA) community has been abuzz with excitement recently. The first two phases of a clinical trial sponsored by Reata Pharmaceuticals showed that the oral therapy omaveloxolone (RTA 408) is safe and led to improvements in some participating patients. However, the U.S. Food and Drug Administration (FDA) determined the results of the trial were not enough for approval of the investigational therapy. Now, members of the FA community are urging Reata to submit…

You must be logged in to read/download the full post.